Zdrowie i gospodarka · 18/04/2016

FDA Announces Public Meeting on Patient-Focused Drug Development for Neuropathic Pain Associated With Peripheral Neuropathy

The FDA is hosting a public meeting to gather patient perspectives on neuropathic pain and treatment approaches, as part of its performance commitments under the Prescription Drug User Fee Act (PDUFA V). The meeting aims to inform the agency's decision-making process when selecting treatments for this condition.